HIV Infections Clinical Trial
Official title:
Left Ventricular Function in HIV-Negative Children Exposed to HIV and HAART In Utero
HIV-uninfected children born to HIV+ women have low level heart problems at birth which may predispose them to heart failure, arrythmias and heart attack later in life. The impact of these heart problems on future heart health is unclear as it is unknown if heart problems in these children persist, worsen or resolve in pre-pubescence. The objective of this study is to characterize heart function in HIV-negative pre-pubertal children born to HIV+ women and exposed to HIV and HAART in utero and compare them to age and gender matched healthy children born to HIV-negative women. Through this objective we will determine if heart problems in HIV-negative children born to HIV+ women and exposed to HAART in utero persists, worsens, or resolves during pre-pubescence.
Significance:
Approximately 700,000 children annually are born to HIV-infected mothers throughout the
world, but with the advent of perinatal highly active antiretroviral therapy (HAART), the
majority of children are born uninfected in Westernized nations and those uninfected are
increasing in developing nations. Uninfected children exposed to HIV and HAART in utero,
have subclinical left ventricular dysfunction (LVD) at birth which may predispose them to
heart failure, conduction abnormalities and myocardial infarction later in life. The impact
of this LVD on future cardiac risk is unclear as it is unknown if LVD in these children
persist, worsen or resolve in pre-pubescence.
Study objectives:
The objective of this study is to characterize left ventricular function in HIV-negative
pre-pubertal children born to HIV+ women and exposed to HIV and HAART in utero and compare
them to age and gender matched healthy children born to HIV-negative women. Through this
objective we will determine if LVD in HIV-negative children born to HIV+ women and exposed
to HAART in utero persists, worsens, or resolves during pre-pubescence. If LVD persists or
worsens in pre-pubescence, these data will lead to future studies examining mechanisms of
and treatments for LVD in these children and will significantly impact the clinical
monitoring and care of these children. If LVD resolves during pre-pubescence, then these
data will provide important information that clinical cardiac monitoring may not be critical
in this population.
Methods:
We plan to examine left ventricular function in 30 HIV-negative children born to HIV+ women
and exposed to HAART in utero and compare them to 30 healthy age and gender matched children
born to HIV-negative women. Left ventricular function will be examined by 2-D, Doppler and
Tissue Doppler imaging echocardiography using a General Electric Vivid 7® ultrasound
machine. Left ventricular measures will include left ventricular structure and dimensions,
systolic and diastolic flow rates, wall velocities during systole and diastole and systolic
and diastolic strain and strain rates (sensitive measures of myocardial contractility).
Echocardiographic measures will take place in the Cardiovascular Imaging Laboratory (CVIL)
at Washington University School of Medicine by a certified cardiac ultrasonographer and data
will be processed, analyzed and interpreted by the ultrasonographer, a consulting
cardiologist and the principal investigator.
Outcomes:
Primary outcomes will include measures of left ventricular function: left ventricular mass,
left ventricular end diastolic dimension, fractional shortening, systolic and diastolic wall
velocities (tissue Doppler imaging) and systolic and diastolic strain and strain rates (2-D
speckle tracking methodology).
;
Observational Model: Case Control, Time Perspective: Cross-Sectional
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
| Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
| Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
| Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
| Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
| Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
| Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
| Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
| Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
| Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
| Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
| Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
| Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
| Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
| Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
| Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
| Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
| Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
| Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
| Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |